Literature DB >> 23274598

Alterations in osteopontin modify muscle size in females in both humans and mice.

Eric P Hoffman1, Heather Gordish-Dressman, Virginia D McLane, Joseph M Devaney, Paul D Thompson, Paul Visich, Paul M Gordon, Linda S Pescatello, Robert F Zoeller, Niall M Moyna, Theodore J Angelopoulos, Elena Pegoraro, Gregory A Cox, Priscilla M Clarkson.   

Abstract

PURPOSE: An osteopontin (OPN; SPP1) gene promoter polymorphism modifies disease severity in Duchenne muscular dystrophy, and we hypothesized that it might also modify muscle phenotypes in healthy volunteers.
METHODS: Gene association studies were carried out for OPN (rs28357094) in the FAMuSS cohort (n = 752; mean ± SD age = 23.7 ± 5.7 yr). The phenotypes studied included muscle size (MRI), strength, and response to supervised resistance training. We also studied 147 young adults that had carried out a bout of eccentric elbow exercise (age = 24.0 ± 5.2 yr). Phenotypes analyzed included strength, soreness, and serum muscle enzymes.
RESULTS: In the FAMuSS cohort, the G allele was associated with 17% increase in baseline upper arm muscle volume only in women (F = 26.32; P = 5.32 × 10), explaining 5% of population variance. In the eccentric damage cohort, weak associations of the G allele were seen in women with both baseline myoglobin and elevated creatine kinase. The sexually dimorphic effects of OPN on muscle were also seen in OPN-null mice. Five of seven muscle groups examined showed smaller size in OPN-null female mice, whereas two were smaller in male mice. The query of OPN gene transcription after experimental muscle damage in mice showed rapid induction within 12 h (100-fold increase from baseline), followed by sustained high-level expression through 16 d of regeneration before falling to back to baseline.
CONCLUSION: OPN is a sexually dimorphic modifier of muscle size in normal humans and mice and responds to muscle damage. The OPN gene is known to be estrogen responsive, and this may explain the female-specific genotype effects in adult volunteers.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23274598      PMCID: PMC3631433          DOI: 10.1249/MSS.0b013e31828093c1

Source DB:  PubMed          Journal:  Med Sci Sports Exerc        ISSN: 0195-9131            Impact factor:   5.411


  39 in total

1.  The PEPR GeneChip data warehouse, and implementation of a dynamic time series query tool (SGQT) with graphical interface.

Authors:  Josephine Chen; Po Zhao; Donald Massaro; Linda B Clerch; Richard R Almon; Debra C DuBois; William J Jusko; Eric P Hoffman
Journal:  Nucleic Acids Res       Date:  2004-01-01       Impact factor: 16.971

2.  The integrin alpha(9)beta(1) binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin.

Authors:  Y Yokosaki; N Matsuura; T Sasaki; I Murakami; H Schneider; S Higashiyama; Y Saitoh; M Yamakido; Y Taooka; D Sheppard
Journal:  J Biol Chem       Date:  1999-12-17       Impact factor: 5.157

3.  Fgfr4 is required for effective muscle regeneration in vivo. Delineation of a MyoD-Tead2-Fgfr4 transcriptional pathway.

Authors:  Po Zhao; Giuseppina Caretti; Stephanie Mitchell; Wallace L McKeehan; Adele L Boskey; Lauren M Pachman; Vittorio Sartorelli; Eric P Hoffman
Journal:  J Biol Chem       Date:  2005-11-02       Impact factor: 5.157

4.  The murine gene encoding secreted phosphoprotein 1 (osteopontin): promoter structure, activity, and induction in vivo by estrogen and progesterone.

Authors:  A M Craig; D T Denhardt
Journal:  Gene       Date:  1991-04       Impact factor: 3.688

5.  Post-translationally modified residues of native human osteopontin are located in clusters: identification of 36 phosphorylation and five O-glycosylation sites and their biological implications.

Authors:  Brian Christensen; Mette S Nielsen; Kim F Haselmann; Torben E Petersen; Esben S Sørensen
Journal:  Biochem J       Date:  2005-08-15       Impact factor: 3.857

6.  Dystrophin: the protein product of the Duchenne muscular dystrophy locus.

Authors:  E P Hoffman; R H Brown; L M Kunkel
Journal:  Cell       Date:  1987-12-24       Impact factor: 41.582

7.  Higher neutrophil infiltration mediated by osteopontin is a likely contributing factor to the increased susceptibility of females to alcoholic liver disease.

Authors:  A Banerjee; U M Apte; R Smith; S K Ramaiah
Journal:  J Pathol       Date:  2006-03       Impact factor: 7.996

8.  ACTN3 genotype is associated with human elite athletic performance.

Authors:  Nan Yang; Daniel G MacArthur; Jason P Gulbin; Allan G Hahn; Alan H Beggs; Simon Easteal; Kathryn North
Journal:  Am J Hum Genet       Date:  2003-07-23       Impact factor: 11.025

9.  Functional polymorphisms associated with human muscle size and strength.

Authors:  Paul D Thompson; Niall Moyna; Richard Seip; Thomas Price; Priscilla Clarkson; Theodore Angelopoulos; Paul Gordon; Linda Pescatello; Paul Visich; Robert Zoeller; Joseph M Devaney; Heather Gordish; Stephen Bilbie; Eric P Hoffman
Journal:  Med Sci Sports Exerc       Date:  2004-07       Impact factor: 5.411

10.  Polymorphism of the IGF2 gene, birth weight and grip strength in adult men.

Authors:  Avan Aihie Sayer; Holly Syddall; Sandra D O'Dell; Xiao-He Chen; Patricia J Briggs; R Briggs; Ian N M Day; Cyrus Cooper
Journal:  Age Ageing       Date:  2002-11       Impact factor: 10.668

View more
  23 in total

1.  Genetic Modifiers for Neuromuscular Diseases.

Authors:  Kay-Marie Lamar; Elizabeth M McNally
Journal:  J Neuromuscul Dis       Date:  2014

2.  Identification of a conserved set of upregulated genes in mouse skeletal muscle hypertrophy and regrowth.

Authors:  Thomas Chaillou; Janna R Jackson; Jonathan H England; Tyler J Kirby; Jena Richards-White; Karyn A Esser; Esther E Dupont-Versteegden; John J McCarthy
Journal:  J Appl Physiol (1985)       Date:  2014-11-13

3.  Association Study of Exon Variants in the NF-κB and TGFβ Pathways Identifies CD40 as a Modifier of Duchenne Muscular Dystrophy.

Authors:  Luca Bello; Kevin M Flanigan; Robert B Weiss; Pietro Spitali; Annemieke Aartsma-Rus; Francesco Muntoni; Irina Zaharieva; Alessandra Ferlini; Eugenio Mercuri; Sylvie Tuffery-Giraud; Mireille Claustres; Volker Straub; Hanns Lochmüller; Andrea Barp; Sara Vianello; Elena Pegoraro; Jaya Punetha; Heather Gordish-Dressman; Mamta Giri; Craig M McDonald; Eric P Hoffman
Journal:  Am J Hum Genet       Date:  2016-10-13       Impact factor: 11.025

4.  Osteopontin, inflammation and myogenesis: influencing regeneration, fibrosis and size of skeletal muscle.

Authors:  Charles N Pagel; Dimuthu K Wasgewatte Wijesinghe; Neda Taghavi Esfandouni; Eleanor J Mackie
Journal:  J Cell Commun Signal       Date:  2013-12-08       Impact factor: 5.782

5.  The effects of MyD88 deficiency on disease phenotype in dysferlin-deficient A/J mice: role of endogenous TLR ligands.

Authors:  Kitipong Uaesoontrachoon; Hee-Jae Cha; Beryl Ampong; Arpana Sali; Jack Vandermeulen; Benjamin Wei; Brittany Creeden; Tony Huynh; James Quinn; Kathleen Tatem; Sree Rayavarapu; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  J Pathol       Date:  2013-10       Impact factor: 7.996

6.  Validation of genetic modifiers for Duchenne muscular dystrophy: a multicentre study assessing SPP1 and LTBP4 variants.

Authors:  Janneke C van den Bergen; Monika Hiller; Stefan Böhringer; Linda Vijfhuizen; Hendrika B Ginjaar; Amina Chaouch; Kate Bushby; Volker Straub; Mariacristina Scoto; Sebahattin Cirak; Véronique Humbertclaude; Mireille Claustres; Chiara Scotton; Chiara Passarelli; Hanns Lochmüller; Francesco Muntoni; Sylvie Tuffery-Giraud; Alessandra Ferlini; Annemieke M Aartsma-Rus; Jan J G M Verschuuren; Peter Ac 't Hoen; Pietro Spitali
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-12-04       Impact factor: 10.154

7.  Identification of Auxiliary Biomarkers and Description of the Immune Microenvironmental Characteristics in Duchenne Muscular Dystrophy by Bioinformatical Analysis and Experiment.

Authors:  Xu Han; Jingzhe Han; Ning Wang; Guang Ji; Ruoyi Guo; Jing Li; Hongran Wu; Shaojuan Ma; Pingping Fang; Xueqin Song
Journal:  Front Neurosci       Date:  2022-06-03       Impact factor: 5.152

Review 8.  Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.

Authors:  Joe N Kornegay; Christopher F Spurney; Peter P Nghiem; Candice L Brinkmeyer-Langford; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  ILAR J       Date:  2014

Review 9.  The mdx mouse model as a surrogate for Duchenne muscular dystrophy.

Authors:  Terence A Partridge
Journal:  FEBS J       Date:  2013-04-22       Impact factor: 5.542

10.  An intron variant of the GLI family zinc finger 3 (GLI3) gene differentiates resistance training-induced muscle fiber hypertrophy in younger men.

Authors:  Christopher G Vann; Robert W Morton; Christopher B Mobley; Ivan J Vechetti; Brian K Ferguson; Cody T Haun; Shelby C Osburn; Casey L Sexton; Carlton D Fox; Matthew A Romero; Paul A Roberson; Sara Y Oikawa; Chris McGlory; Kaelin C Young; John J McCarthy; Stuart M Phillips; Michael D Roberts
Journal:  FASEB J       Date:  2021-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.